AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21557868 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition B - cooked green garden beans, pasta and chicken
Number of subjects: 98
Study 21557868 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition AB - carrot sticks, green garden beans, pasta and chicken
Number of subjects: 98
Study 18438256 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-Resistance Circuit (HRC) training
Number of subjects: 10
Study 18438256 — intervention group
Group type: COMPARATOR
Intervention: Traditional Strength (TS) training
Number of subjects: 10
Study 16507973 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational programme
Number of subjects: 100
Study 16507973 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 12925054 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational and solution-focused therapy group intervention
Number of subjects: 77
Study 12925054 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 77
Study 10726795 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vitrectomy (duration between 3-6 months)
Number of subjects: 40
Study 10726795 — intervention group
Group type: COMPARATOR
Intervention: Deferred vitrectomy (duration of more than 6 months)
Number of subjects: 40
Study 9082675 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedisamil 0.3 mg/kg BW
Number of subjects: 32
Study 9082675 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedisamil 0.4 mg/kg BW
Number of subjects: 32
Study 1533595 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term therapeutic intervention directed at airways obstruction and hyperresponsiveness
Number of subjects: 274
Study 1533595 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic intervention directed at airways obstruction alone
Number of subjects: 274
Study 7423284 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 tablets administered intravaginally
Number of subjects: 0
Study 7423284 — intervention group
Group type: COMPARATOR
Intervention: Comparison of the Bishop score
Number of subjects: 0
Study 31778436 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity laser therapy at 1064 nm and 60 J/cm2 for 10 min (HILT)
Number of subjects: 68
Study 31778436 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy at 785 nm and 8 J/cm2 for 8 min (LLLT)
Number of subjects: 68
Study 31778436 — intervention group
Group type: COMPARATOR
Intervention: Sham (HILT placebo)
Number of subjects: 68
Study 31778436 — intervention group
Group type: COMPARATOR
Intervention: Sham (LLLT placebo)
Number of subjects: 68
Study 28179223 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain-rich diet (207 ± 39 g whole grains plus 40 ± 5 g dietary fiber/d)
Number of subjects: 81
Study 28179223 — intervention group
Group type: COMPARATOR
Intervention: Refined grain-based diet (0 g whole grains plus 21 ± 3 g dietary fiber/d)
Number of subjects: 81
Study 25894405 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus acidophilus, L. plantarum, Bifidobacterium lactis, Saccharomyces boulardii)
Number of subjects: 0
Study 25894405 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 25894405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22867838 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bimanual laryngoscopy (group M)
Number of subjects: 78
Study 22867838 — intervention group
Group type: COMPARATOR
Intervention: Conventional bimanual laryngoscopy (group C)
Number of subjects: 78
Study 21199097 — intervention group
Group type: EXPERIMENTAL
Intervention: ECA (ethylcyanoacrylate tissue adhesive)
Number of subjects: 36
Study 21199097 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene sutures
Number of subjects: 36
Study 19875425 — intervention group
Group type: EXPERIMENTAL
Intervention: Active strategies to implement the Canadian C‐Spine Rule including education, policy, and real-time reminders on radiology requisitions.
Number of subjects: 11824
Study 19875425 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention introduced to alter the behaviour of doctors requesting cervical spine imaging.
Number of subjects: 11824
Study 17206669 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninflamed ileal mucosa
Number of subjects: 22
Study 17206669 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflamed ileal mucosa
Number of subjects: 22
Study 17206669 — intervention group
Group type: COMPARATOR
Intervention: Comparison of noninflamed and inflamed mucosa
Number of subjects: 22
Study 17277655 — intervention group
Group type: EXPERIMENTAL
Intervention: Gloved fingers
Number of subjects: 15
Study 17277655 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic instruments
Number of subjects: 15
Study 17277655 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic instrument with sensor
Number of subjects: 15
Study 12729938 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of sustained‐release melatonin
Number of subjects: 58
Study 12729938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 9917048 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% cocaine solution for 10 min (160 mg)
Number of subjects: 12
Study 9917048 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% cocaine solution for 20 min (160 mg)
Number of subjects: 12
Study 9917048 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% cocaine solution for 20 min (400 mg)
Number of subjects: 12
Study 7485287 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic FHR monitoring
Number of subjects: 1419
Study 7485287 — intervention group
Group type: COMPARATOR
Intervention: Intermittent auscultation
Number of subjects: 1419
Study 2186909 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily netilmicin (n = 98)
Number of subjects: 197
Study 2186909 — intervention group
Group type: COMPARATOR
Intervention: Thrice daily netilmicin (n = 99)
Number of subjects: 197
Study 6986939 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 40
Study 6986939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6986939 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo
Number of subjects: 40
Study 6986939 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 40
Study 6986939 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine plus exposure
Number of subjects: 40
Study 30729945 — intervention group
Group type: COMPARATOR
Intervention: Syringe irrigation (SI) with distilled water (DW)
Number of subjects: 105
Study 30729945 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe irrigation (SI) with 2.5% NaOCl
Number of subjects: 105
Study 30729945 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe irrigation (SI) with 2.5% Ca(OCl)2
Number of subjects: 105
Study 30729945 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser‐activated irrigation (LAI) with distilled water (DW)
Number of subjects: 105
Study 30729945 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser‐activated irrigation (LAI) with 2.5% NaOCl
Number of subjects: 105
Study 30729945 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser‐activated irrigation (LAI) with 2.5% Ca(OCl)2
Number of subjects: 105
Study 30729945 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser‐activated irrigation (LAI) with no solution
Number of subjects: 105
Study 28467859 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol (20 mg)
Number of subjects: 0
Study 28467859 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg)
Number of subjects: 0
Study 28467859 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of theophylline and bambuterol
Number of subjects: 0
Study 28467859 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol
Number of subjects: 0
Study 25169679 — intervention group
Group type: EXPERIMENTAL
Intervention: Information sheet with both implementation intentions and explicit commitment
Number of subjects: 937
Study 25169679 — intervention group
Group type: COMPARATOR
Intervention: Control condition (information sheet only)
Number of subjects: 937
Study 23938173 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (50-200 mg/day)
Number of subjects: 24
Study 23938173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23938173 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 24
Study 21232120 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg/day
Number of subjects: 24
Study 21232120 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day
Number of subjects: 24
Study 18497592 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week psychoeducative nursing intervention
Number of subjects: 83
Study 18497592 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 16634542 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9426 0.3 mg x kg(‐1)
Number of subjects: 78
Study 16634542 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9426 0.6 mg x kg(‐1)
Number of subjects: 78
Study 16634542 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9426 0.9 mg x kg(‐1)
Number of subjects: 78
Study 12738151 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 micro g, followed by two doses of oral misoprostol 100 micro g 4 hours apart (Group 2)
Number of subjects: 1574
Study 12738151 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of oxytocin 10 IU plus oral misoprostol 400 micro g, followed by two doses of oral misoprostol 100 micro g 4 hours apart (Group 1)
Number of subjects: 1574
Study 12738151 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of oxytocin 10 IU plus intramuscular administration of methylergonovine maleate 0.2 mg (Group 4)
Number of subjects: 1574
Study 11015543 — intervention group
Group type: EXPERIMENTAL
Intervention: Dust control intervention (cleaning equipment and up to 8 visits by a trained lead hazard control advisor)
Number of subjects: 275
Study 11015543 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 275
Study 8857441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine infusion at a dose of 2 microg kg-1 min-1, titrated to achieve normal blood pressure, urine output, and base deficit.
Number of subjects: 17
Study 8857441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine infusion
Number of subjects: 17
Study 1507375 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (two 325‐mg tablets once per day)
Number of subjects: 3711
Study 1507375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3711
Study 6305546 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (6 micrograms/kg/hr)
Number of subjects: 6
Study 6305546 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg)
Number of subjects: 6
Study 6305546 — intervention group
Group type: COMPARATOR
Intervention: D5/W (placebo)
Number of subjects: 6
Study 31432311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite gel
Number of subjects: 46
Study 31432311 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 46
Study 28259320 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 MG plus Metronidazole 500 MG 3 times a day for 3 or 7 days
Number of subjects: 0
Study 28259320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27006286 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (low dose)
Number of subjects: 0
Study 27006286 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control group)
Number of subjects: 0
Study 24927970 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (70 mg/day for 72 hours)
Number of subjects: 100
Study 24927970 — intervention group
Group type: COMPARATOR
Intervention: Control (no trimetazidine)
Number of subjects: 100
Study 22341495 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated connectors
Number of subjects: 25
Study 22341495 — intervention group
Group type: COMPARATOR
Intervention: Non-coated connectors
Number of subjects: 25
Study 19071066 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable gastric stimulation (stimulation on)
Number of subjects: 190
Study 19071066 — intervention group
Group type: COMPARATOR
Intervention: Standard diet and behavioral therapy (stimulation off)
Number of subjects: 190
Study 17214729 — intervention group
Group type: EXPERIMENTAL
Intervention: Allylamine-benzoyl peroxide combination therapy
Number of subjects: 23
Study 17214729 — intervention group
Group type: COMPARATOR
Intervention: Proactiv Solution (benzoyl peroxide alone)
Number of subjects: 23
Study 15565082 — intervention group
Group type: EXPERIMENTAL
Intervention: General low-fat advice with additional targets for food sources of unsaturated fats
Number of subjects: 0
Study 15565082 — intervention group
Group type: COMPARATOR
Intervention: General low-fat advice (control group)
Number of subjects: 0
Study 11408420 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (1 l/h of a 6% carbohydrate beverage)
Number of subjects: 98
Study 11408420 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 98
Study 9231212 — intervention group
Group type: EXPERIMENTAL
Intervention: artemisinin suppositories followed by mefloquine
Number of subjects: 109
Study 9231212 — intervention group
Group type: EXPERIMENTAL
Intervention: intramuscular artesunate followed by mefloquine
Number of subjects: 109
Study 9231212 — intervention group
Group type: COMPARATOR
Intervention: intravenous quinine followed by pyrimethamine/sulfadoxine
Number of subjects: 109
Study 8094279 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly alternating zidovudine (200 mg every 4 hours) and ddC (0.03 mg/kg every 4 hours)
Number of subjects: 131
Study 8094279 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly intermittent zidovudine (200 mg every 4 hours)
Number of subjects: 131
Study 8094279 — intervention group
Group type: COMPARATOR
Intervention: Continuous zidovudine therapy
Number of subjects: 131
Study 8094279 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating regimens (zidovudine and ddC)
Number of subjects: 131
Study 8094279 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating therapy with zidovudine and ddC
Number of subjects: 131
Study 8094279 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating therapy limbs
Number of subjects: 131
Study 8094279 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone (intermittently or continuously)
Number of subjects: 131
Study 3113240 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of misoprostol
Number of subjects: 12
Study 3113240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31419323 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT1
Number of subjects: 14
Study 31419323 — intervention group
Group type: COMPARATOR
Intervention: calcipotriol 0.005%
Number of subjects: 14
Study 29906642 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 118
Study 29906642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 27438170 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonintubated ETS using a needle endoscope (group A, n=108)
Number of subjects: 221
Study 27438170 — intervention group
Group type: COMPARATOR
Intervention: Traditional transaxillary single-port ETS using a 5-mm thoracoscope (group B, n=113)
Number of subjects: 221
Study 25011667 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive motor task under vibratory feedback and 3D motor characterization
Number of subjects: 44
Study 25011667 — intervention group
Group type: COMPARATOR
Intervention: 3D motor characterization only
Number of subjects: 44
Study 23229457 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-midvastus approach
Number of subjects: 89
Study 23229457 — intervention group
Group type: COMPARATOR
Intervention: mini-medial parapatellar approach
Number of subjects: 89
Study 23229457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 89
Study 20448107 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan-prednisone and thalidomide (MPT)
Number of subjects: 363
Study 20448107 — intervention group
Group type: COMPARATOR
Intervention: Melphalan-prednisone and placebo (MP)
Number of subjects: 363
Study 18566593 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan
Number of subjects: 369
Study 18566593 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril
Number of subjects: 369
Study 18566593 — intervention group
Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 369
Study 16336334 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral vapour resection of the prostate (TUVRP)
Number of subjects: 150
Study 16336334 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HOLEP)
Number of subjects: 150
Study 16336334 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 150
Study 12829910 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC + MMF
Number of subjects: 223
Study 12829910 — intervention group
Group type: COMPARATOR
Intervention: CsA + MMF
Number of subjects: 223
Study 12829910 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC + AZA
Number of subjects: 223
Study 10743480 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein soya milk
Number of subjects: 21
Study 10743480 — intervention group
Group type: COMPARATOR
Intervention: Cows' milk
Number of subjects: 21
Study 7496696 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 270 mgI ml‐1
Number of subjects: 140
Study 7496696 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol 300 mgI ml‐1
Number of subjects: 140
Study 1675534 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide
Number of subjects: 106
Study 1675534 — intervention group
Group type: COMPARATOR
Intervention: Topical meclocycline sulfosalicylate
Number of subjects: 106
Study 1675534 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (topical meclocycline sulfosalicylate and benzoyl peroxide)
Number of subjects: 106
Study 1675534 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 106
Study 6799032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium therapy
Number of subjects: 38
Study 6799032 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 38
Study 31412895 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard TB therapy (for HIV-positive patients)
Number of subjects: 262
Study 31412895 — intervention group
Group type: COMPARATOR
Intervention: Standard TB therapy (for HIV-negative patients)
Number of subjects: 262
Study 31412895 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard TB therapy (for both groups)
Number of subjects: 262
Study 29135593 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic needle tip positioning technique (n = 132)
Number of subjects: 260
Study 29135593 — intervention group
Group type: COMPARATOR
Intervention: Palpation technique (n = 128)
Number of subjects: 260
Study 27855166 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG-F
Number of subjects: 35
Study 27855166 — intervention group
Group type: COMPARATOR
Intervention: Thymoglobulin
Number of subjects: 35
Study 25001153 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 534
Study 25001153 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 534
Study 22463733 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed home medicines review service
Number of subjects: 100
Study 22463733 — intervention group
Group type: COMPARATOR
Intervention: Usual post-discharge care
Number of subjects: 100
Study 20049950 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-dependent release formulation 3.6 g/day
Number of subjects: 229
Study 20049950 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-dependent release formulation 2.4 g/day
Number of subjects: 229
Study 20049950 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-dependent release formulation 2.25 g/day
Number of subjects: 229
Study 20049950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 20049950 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-dependent release formulations (2.4 g and 3.6 g)
Number of subjects: 229
Study 18411384 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin therapy using glargine self-titrated according to a patient algorithm
Number of subjects: 405
Study 18411384 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with physician-adjusted doses of oral agents
Number of subjects: 405
Study 16080936 — intervention group
Group type: EXPERIMENTAL
Intervention: Seprafilm
Number of subjects: 122
Study 16080936 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 122
Study 11834996 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate spinal cord decompression (protocol group)
Number of subjects: 91
Study 11834996 — intervention group
Group type: COMPARATOR
Intervention: Reference group (non-protocol patients)
Number of subjects: 91
Study 10187866 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Units (SUs)
Number of subjects: 14308
Study 10187866 — intervention group
Group type: COMPARATOR
Intervention: General Wards (GWs)
Number of subjects: 14308
Study 7497137 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular mammographic screening every 33 months (every 24 months for those aged 40-49)
Number of subjects: 21925
Study 7497137 — intervention group
Group type: COMPARATOR
Intervention: Unscreend control group
Number of subjects: 21925
Study 1690342 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 0
Study 1690342 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 0
Study 397711 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 15 mg (maximum 90 mg)
Number of subjects: 16
Study 397711 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 4 mg (maximum 24 mg)
Number of subjects: 16
Study 6287928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal enviroxime (one spray per nostril, five times per day)
Number of subjects: 40
Study 6287928 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40